Skip to main content
. 2022 Apr 18;18(7):2949–2961. doi: 10.7150/ijbs.68438

Figure 1.

Figure 1

UCP1 was positively related to a better prognosis of breast cancer. (A) Expression of UCP1 in normal breast tissue (n=114), luminal (n=566), HER2 positive (n=37) and different triplenegative (n=153) subclass. (B) Expression of UCP1 based on breast cancer individual stages. Normal (n=114), stage 1 (n=183), stage 2 (n=615), stage 3 (n=247), stage 4 (n=20). (C) Expression of UCP1 based on nodal metastasis. Normal (n=114), N0 (n=516), N1 (n=362), N2 (n=120), N3 (n=77). (D) Expression of UCP1 based on TP53 mutation status. TP53 mutant (n=334), TP53 non-mutant (n=698) (E) Disease free survival curve of high UCP1 expression and low UCP1 expression, present by months. (F) Overall survival curve of high UCP1 expression and low UCP1 expression, present by months. (G) Immunohistochemical staining of UCP1 in adenosis sample (normal breast control), (H) invasive ductal carcinoma, (I) neuroendocrine carcinoma, and (J) invasive lobular carcinoma. (K) Protein and (L) mRNA expression of UCP1 in MCF-10A and BT549.*:p<0.05,**:p<0.01,***:p<0.001